Research programme: urotensin-II receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: urotensin-II receptor antagonists - GlaxoSmithKline

Alternative Names: SB328872; SB436811; SB657510

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Pyrrolidines; Sulfonamides
  • Mechanism of Action Urotensin II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Atherosclerosis; Diabetes mellitus; Heart failure; Hypertension

Most Recent Events

  • 03 Sep 2008 Final pharmacodynamics data from a preclinical trial in Pressure-overload hypertrophy presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 21 Aug 2006 Preclinical trials in Diabetes mellitus in United Kingdom (unspecified route)
  • 21 Aug 2006 Preclinical trials in Heart failure in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top